  Medical devices with matrix metalloproteinase (MMP) modulating functionality
are highly desirable to restore tissue homeostasis in critical inflammation
states, such as chronic wounds, rotator cuff tears and cancer. The introduction
of MMP-modulating functionality in such devices is typically achieved via
loading of either rapidly-diffusing chelating factors, e.g. EDTA, or
MMP-cleavable substrates, raising issues in terms of non-controllable
pharmacokinetics and enzymatic degradability, respectively. Aiming to
accomplish inherent, long-term, device-induced MMP regulation, this study
investigated the synthesis of a hydroxamic acid (HA)-methacrylated collagen
conjugate as the building block of a soluble factor-free MMP-modulating
hydrogel network with controlled enzymatic degradability. This was realised via
a two-step synthetic route: (i) type I collagen was functionalised with
photonetwork-inducing methacrylic anhydride (MA) adducts; (ii) this
methacrylated product was activated with a water-soluble carbodiimide prior to
reaction with hydroxylamine, resulting in MMP-chelating HA functions.
Nearly-quantitative methacrylation of collagen amines was observed via
2,4,6-trinitrobenzenesulfonic acid (TNBS) assay. The molar content of HA
adducts was indirectly quantified via conversion of remaining carboxyl
functions into ethylenediamine (EDA), so that 12-16 mol.% HA was revealed in
the conjugate. Resulting UV cured, HA-bearing collagen hydrogels proved to
induce up to ~13 and ~32 RFU% activity reduction of MMP-9 and MMP-3,
respectively, following 4-day incubation in vitro. No hydrogel-induced toxic
response was observed following 4-day culture of G292 cells. The novel
synthetic strategies described in this work provide a new insight into the
systematic chemical manipulation of collagen materials aiming at the design of
biomimetic, inflammation-responsive medical devices.
